Sign In
Buy MRK
$115.49
+0.320 (+0.278%)
At Close: Jun 17, 2026
4-Factor Dividend Growth Portfolio - Sour Month
12:35pm, Wednesday, 19'th Apr 2023
The 4-factor dividend growth portfolio was launched on November 1st, 2022, and despite a poor start to April the long term return is still attractive. The portfolio outperformed the S&P 500 Total Retu
Is Merck Stock a Screaming Buy After This $11 Billion Acquisition?
10:45am, Wednesday, 19'th Apr 2023
Ramping up its immunology pipeline with Prometheus Biosciences could help it move beyond Keytruda's eventual loss of exclusivity. Even so, the drugmaker faces several key challenges in this highly com
GSK, Merck deals show appetite is ripe for biopharmaceutical M&A
04:56pm, Tuesday, 18'th Apr 2023
Biopharmaceutical companies are getting stock price lifts this week after two big deals in the space signal that M&A appetite is ripe. On Tuesday, GSK PLC (LSE:GSK, NYSE:GSK) revealed it has paid ar
Final Trades: XBI, BXP, SPY & MRK
06:41pm, Monday, 17'th Apr 2023
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Wells Fargo's Mohit Bansal on Merck's $10.8B deal to buy Prometheus
05:55pm, Monday, 17'th Apr 2023
Mohit Bansal, Wells Fargo securities analyst, joins 'Closing Bell: Overtime' to discuss Merck's acquisition of Prometheus and Moderna's positive cancer therapy trial results.
Merck and Sega Usher M&A Into Spring Renaissance
03:09pm, Monday, 17'th Apr 2023
Liana Baker has more on Merck buying Prometheus for $10.8 billion in cash and Sega buying Rovio Entertainment in a deal that values the creator of Angry Birds at about 706 million ($776 million). S
Roivant Sciences shares spike on Merck-Prometheus Biosciences deal
12:23pm, Monday, 17'th Apr 2023
Roivant Sciences shares took off on the news that Merck is acquiring Prometheus Biosciences in a $10.8 billion deal as investors placed their bets on which of the two companies could be first to br
Merck's Prometheus Acquisition Is A Step In The Right Direction
12:09pm, Monday, 17'th Apr 2023
Merck is facing the LOE on Keytruda before the end of the decade, which makes up more than 35% of the company's revenue. The company has an impressive portfolio of assets, but its pipeline is sparse a
Merck Nabs Prometheus Bio For $10.8 Billion As Keytruda Patent Expirations Loom
10:21am, Monday, 17'th Apr 2023
Merck is acquiring Prometheus Bio in a well-timed $10.8 billion deal ahead of Keytruda's patent loss. The news sent RXDX stock flying Monday.
Merck agrees to acquire Prometheus Biosciences
09:55am, Monday, 17'th Apr 2023
Yahoo Finance's Anjalee Khemlani joins the Live show to discuss news that Merck has agreed to acquire biotechnology company Prometheus Biosciences.
Merck's $10.8 Billion Prometheus Deal Has Citi Analysts Bullish
08:56am, Monday, 17'th Apr 2023
Prometheus' PRA023 drug can add 15% to 30% to Merck's long-term earnings once approved, according to Citi analysts.
Merck makes US$11bn swoop for California biotech
03:13am, Monday, 17'th Apr 2023
Merck & Co Inc (NYSE:MRK) is set to acquire Prometheus Biosciences for $10.8bn in an all-cash deal, as the US drugmaker aims to bolster its pipeline. San Diego-based Prometheus focuses on diseases c
Merck Offers to Buy Prometheus for $10.8 Billion
09:49pm, Sunday, 16'th Apr 2023
Merck & Co. Inc. has agreed to buy Prometheus Biosciences Inc. for about $10.8 billion. Su Keenan reports on Bloomberg Television.
Moderna, Merck combo cancer-vaccine treatment shows ‘significant' promise
05:21pm, Sunday, 16'th Apr 2023
A cancer vaccine developed by Moderna Inc. and Merck & Co. Inc. showed promising results in a key study, reducing the risk of recurrence or death by 44%, the drug makers said Sunday.
Merck in Late-Stage Talks to Acquire Prometheus Biosciences
12:01am, Sunday, 16'th Apr 2023
Merck & Co. is in late-stage talks to acquire Prometheus Biosciences Inc., according to people familiar with the matter, a move that could give the big drugmaker promising immune disease treatments.
